Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nasdaq  >  Gilead Sciences, Inc.    GILD

Delayed Quote. Delayed  - 07/22 10:00:00 pm
86.55 USD   -0.79%
07/22 GILEAD SCIENCES : European CHMP Adopts Positive Opinion on Gilead&rs..
07/21 GILEAD SCIENCES : Odefsey® (Emtricitabine, Rilpivirine, Tenofovir Al..
07/18 GILEAD SCIENCES : to Release Second Quarter 2016 Financial Results o..
News SummaryMost relevantAll newsSector news 

Gilead Sciences, Inc. : FDA Panel Backs Gilead's HIV 'Quad' Medicine

share with twitter share with LinkedIn share with facebook
share via e-mail
05/11/2012 | 09:06pm CEST
   By Jennifer Corbett Dooren 

A federal advisory panel Friday backed an experimental Gilead Sciences Inc. (GILD) HIV medicine known as the Quad.

The company is seeking approval from the Food and Drug Administration to market the product, which combines four active ingredients into one pill, meant to be taken once daily.

The medicine was reviewed on Friday by the agency's antiviral drugs advisory panel, which is made up of non-FDA medical experts. The panel voted 13 to 1 on a question that asked if the submitted clinical data supported approval of the drug. The panel vote amounts to a recommendation that the FDA approve the drug. The agency usually follows panel recommendations but isn't required to. The FDA is expected to make a decision by the end of August.

Quad is a combination of four active ingredients in one pill. It combines Gilead's double-drug Truvada, the drug elvitegravir and an agent that boosts blood levels of certain HIV drugs, cobicistat.

Gilead is hoping that the one-pill, once-daily Quad regimen will provide more convenience to HIV patients, many of whom now take multiple pills for treatment. Some analysts think it could become a blockbuster seller.

-By Jennifer Corbett Dooren; Dow Jones Newswires, 202-862-9294; jennifer.corbett@dowjones.com

share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on GILEAD SCIENCES, INC.
07/22 GILEAD SCIENCES : European CHMP Adopts Positive Opinion on Gilead’s Type I..
07/21 GILEAD SCIENCES : Odefsey® (Emtricitabine, Rilpivirine, Tenofovir Alafenamide) M..
07/21 GILEAD SCIENCES : European Commission Grants Marketing Authorization for Gilead'..
07/18 GILEAD SCIENCES : to Release Second Quarter 2016 Financial Results on Monday, Ju..
07/14 GILEAD SCIENCES : PREVAIL treatment trial for men with persistent Ebola viral RN..
07/14 GILEAD SCIENCES : Investigators at Gilead Sciences Inc. Zero in on Antiretrovira..
07/14 GILEAD SCIENCES : Findings in Reverse Transcriptase Inhibitor Therapy Reported f..
07/14 GILEAD SCIENCES : Patent Issued for Salts of HIV Inhibitor Compounds (USPTO 9381..
07/14 GILEAD SCIENCES : receives approval in Canada for EPCLUSA™ (sofosbuvir/vel..
07/14 GILEAD SCIENCES : Meeting urges hepatitis C awareness
More news
Sector news : Bio Therapeutic Drugs
07/21DJAmgen and Allergan Study Finds Biosimilar Comparable to Herceptin
07/12DJAmgen Biosimilar Gets Thumbs-Up From FDA Panel
07/12DJJuno to Resume Clinical Trial of Anticancer Treatment
07/09DJCorrections & Amplifications -- WSJ
07/08DJAMGEN : Theranos Dealt Blow as Holmes Is Banned From -2-
More sector news : Bio Therapeutic Drugs
News from SeekingAlpha
12:36p MY EARNINGS GAME PLAN : July 25-27
12:05p TOP 10 HEALTH CARE STOCKS : Which To Buy? Part 3
07/22 GILEAD : Q2 Earnings Crucial
07/22 BIOTECH FORUM DAILY DIGEST : Relypsa Gets Bought Out, Biogen's Big Beat, Biotech..
07/22 European Ad Comm backs pre-exposure prophylaxis labeling for Gilead's HIV med..
Financials ($)
Sales 2016 31 021 M
EBIT 2016 20 700 M
Net income 2016 15 369 M
Debt 2016 5 208 M
Yield 2016 2,14%
P/E ratio 2016 7,79
P/E ratio 2017 7,28
EV / Sales 2016 3,88x
EV / Sales 2017 3,68x
Capitalization 115 269 M
More Financials
Duration : Period :
Gilead Sciences, Inc. Technical Analysis Chart | GILD | US3755581036 | 4-Traders
Full-screen chart
Technical analysis trends GILEAD SCIENCES, ...
Short TermMid-TermLong Term
Technical analysis
Income Statement Evolution
More Financials
Mean consensus OUTPERFORM
Number of Analysts 25
Average target price 112 $
Spread / Average Target 29%
Consensus details
EPS Revisions
More Estimates Revisions
John F. Milligan President, Chief Executive Officer & Director
John C. Martin Executive Chairman
Kevin B. Young Chief Operating Officer
Robin L. Washington Chief Financial Officer & Executive Vice President
Norbert W. Bischofberger Chief Scientific Officer & Executive VP-Research
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
GILEAD SCIENCES, INC.-14.47%115 269
AMGEN, INC.2.06%124 454
ACTELION LTD22.85%19 820
More Results